RGNX Financials
Regenxbio Inc - Financial statements & key metrics
Stock Price
$9.43
Market Cap
$440.40M
P/E Ratio
-2.1
EPS
$-3.46
Income Statement Highlights
Most Recent Quarter: 2024-12-31
Revenue
$83.33M
Gross Profit
-
Operating Income
-
Net Income
$-227.10M
EPS (Diluted)
$-4.59
Balance Sheet Highlights
Total Assets
$465.99M
Total Liabilities
$206.34M
Shareholders Equity
-
Cash & Equivalents
$57.53M
Total Debt
-
Cash Flow Highlights
Operating Cash Flow
$-173.13M
CapEx
-
Free Cash Flow
-
Profitability Metrics
Operating Margin
-176.3%
Net Margin
-110.3%
ROE
-76.9%
View Complete Financial Statements
Full income statements, balance sheets, and cash flows for multiple periods
Open Full FinancialsFrequently Asked Questions
What is RGNX revenue?
RGNX's most recent quarterly revenue was $83.33M. Annual revenue can be calculated by summing the four most recent quarters.
Is RGNX profitable?
RGNX reported a loss of $227.10M in the most recent quarter. The net profit margin is -110.3%.
What is RGNX market cap?
RGNX has a market capitalization of $440.40M, making it a small-cap stock.
Does RGNX have debt?
View RGNX's balance sheet for debt information.
What is RGNX cash flow?
Cash flow data is available in the full financial statements.